September 25, 2009 --More studies are questioning the reliability of a common prostate cancer screening test. They found the inability of the prostate antigen screening test, or PSA, to distinguish between deadly and harmless prostate cancers makes it unusable as a population wide screening tool. Because of this unreliability, results from the test lead to overdiagnosis and overtreatment.
Researchers say men should be thoroughly informed about the PSA test and know the test cannot tell whether they have a life threatening cancer.
The studies appear in the online edition of the BMJ Journal.